FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular methods for the treatment or inhibition of eosinophilic asthma, eosinophilic COPD, eosinophilic ACO and nasal polyps in a subject with one or more number of risk alleles in an intron variant rs1420101 IL1RL1, in a variant rs1342326 IL33, in both or in their variants in non-equilibrium coupling.
EFFECT: obtaining methods for the treatment or inhibition of inflammatory lung diseases.
72 cl, 9 dwg, 9 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MULTIVALENT AND MULTI-SPECIFIC 41BB-BINDING FUSED PROTEINS | 2017 |
|
RU2789648C2 |
| ANTI-LILRB1 ANTIBODY AND USES THEREOF | 2021 |
|
RU2813373C1 |
| HETERODIMERIC FC-FUSED PROTEINS IL15/IL15Rα | 2017 |
|
RU2779938C2 |
| ANTI-LILRB1 ANTIBODY AND ITS USE | 2020 |
|
RU2801535C1 |
| ANTIBODIES TO TAU AND THEIR USE | 2018 |
|
RU2787779C2 |
| ANTI-PVRIG ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732042C2 |
| BISPECIFIC ANTIBODIES | 2020 |
|
RU2818588C2 |
| ANTIBODIES BINDING TO HUMAN CANNABINOID RECEPTOR 1 (CB1) | 2015 |
|
RU2730674C2 |
| PARTICLES CONJUGATED TO PEPTIDE | 2014 |
|
RU2813163C2 |
| POLYPEPTIDE COMPRISING ANTIGEN-BINDING DOMAIN AND TRANSPORT SEGMENT | 2018 |
|
RU2815452C2 |
